

August 6, 2025-

Kyoto Drug Discovery & Development to Present Phase 2 Clinical Trial Results of KUS121 for CRAO at Retina Society Annual Meeting

Kyoto, Japan – Kyoto Drug Discovery & Development Co., Ltd. (KDDD), a biotechnology company developing novel therapies for retinal diseases, today announced that the efficacy results from its Phase 2 clinical trial of KUS121 for the treatment of acute central retinal artery occlusion (CRAO) have been accepted for presentation in the Late-Breaking Abstract Session at the Retina Society's 58th Annual Scientific Meeting, to be held in Chicago, Illinois, in September 2025.

The Retina Society Annual Meeting is a globally recognized forum highlighting cutting-edge clinical and basic research in retinal disease. The Late-Breaking Abstract Session is reserved for the most recent and significant scientific findings.

The presentation will showcase efficacy results from a multicenter, randomized, sham-controlled clinical trial conducted in the United States. In this trial, KUS121 was administered via intravitreal injection once daily for three consecutive days in patients with CRAO, a condition characterized by sudden and often irreversible vision loss and a poor visual prognosis. The study was designed to evaluate both the efficacy and safety of KUS121.

Trial details are available on [ClinicalTrials.gov](https://clinicaltrials.gov) under the identifier NCT06178055.

Presentation Details

- Conference: The Retina Society 58th Annual Scientific Meeting
- Dates: Thursday, September 11 – Sunday, September 14, 2025
- Venue: The Ritz-Carlton, Chicago, Illinois, USA
- Presentation Time: Friday, September 12, 2025, at 4:05 PM (local time)
- Session: Late-Breaking Abstract Session
- Presentation Title: Intravitreal KUS121 for Acute Central Retinal Artery Occlusion: Results from a Phase 2 Randomized, Sham-Controlled Trial

KDDD remains committed to developing innovative therapies for serious retinal diseases that currently lack effective treatment options.

About KUS121

KUS121 (Kyoto University Substances) is a first-in-class neuroprotective agent that inhibits the ATPase activity of valosin-containing protein (VCP), thereby preserving intracellular ATP levels and preventing cell death. Originally developed by researchers at Kyoto University, KUS121 is being evaluated as a potential treatment for CRAO—an ophthalmic emergency with limited therapeutic options. A physician-initiated Phase I/II trial in Japan demonstrated the safety and potential efficacy of intravitreal KUS121. The U.S.-based Phase II “GION Study” (named after Kyoto’s historic district) commenced in early 2024. KUS121 is expected to become the first approved therapeutic specifically for CRAO.

About Kyoto Drug Discovery & Development Co., Ltd. (KDDD)

Kyoto Drug Discovery & Development Co., Ltd. is a Kyoto University spin-out biotechnology company focused on the development of novel neuroprotective treatments. The company’s lead program, KUS121, targets severe ophthalmic diseases such as retinal artery occlusion (RAO) and is also being explored for broader therapeutic applications beyond ophthalmology.

For further information, please visit: <https://www.kyoto-drug.com>

Contact: Kyoto Drug Discovery and Development Co., Ltd.

Email: info@kyoto-drug.com